• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.

作者信息

Fu Weijun, Bang Soo-Mee, Huang Honghui, Kim Kihyun, Li Wei, An Gang, Lee Je-Jung, Cai Zhen, Jin Jie, Wang Yafei, Chim Chor Sang, Carson Robin, Liu Rui, Zhao Man, Chen Xi, Cui Canchan, Hou Jian, Wang Jianxiang

机构信息

Shanghai Changzheng Hospital, Shanghai, China.

Seoul National University Bundang Hospital, Seongnam, South Korea.

出版信息

Ann Hematol. 2024 Nov;103(11):4835-4836. doi: 10.1007/s00277-024-06020-3.

DOI:10.1007/s00277-024-06020-3
PMID:39311958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534979/
Abstract
摘要

相似文献

1
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.对以下内容的更正：达雷妥尤单抗、硼替佐米、美法仑和泼尼松与单独使用硼替佐米、美法仑和泼尼松治疗移植不适用的亚洲新诊断多发性骨髓瘤患者：3期OCTANS研究的最终分析
Ann Hematol. 2024 Nov;103(11):4835-4836. doi: 10.1007/s00277-024-06020-3.
2
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.达雷妥尤单抗、硼替佐米、美法仑和泼尼松与单独使用硼替佐米、美法仑和泼尼松治疗新诊断的不适宜移植的亚洲多发性骨髓瘤患者的比较：3期OCTANS研究的最终分析
Ann Hematol. 2025 Jan;104(1):515-525. doi: 10.1007/s00277-024-05958-8. Epub 2024 Sep 4.
3
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.硼替佐米、美法仑和泼尼松联合或不联合达雷妥尤单抗治疗不适合移植的初诊亚洲多发性骨髓瘤患者：III 期 OCTANS 研究。
Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):446-455.e4. doi: 10.1016/j.clml.2023.02.009. Epub 2023 Mar 4.
4
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.硼替佐米、美法仑和泼尼松联合或不联合达雷妥尤单抗用于新诊断的不适于移植的多发性骨髓瘤患者（ALCYONE）：一项开放标签、随机、多中心、3期试验的最终分析
Lancet Oncol. 2025 May;26(5):596-608. doi: 10.1016/S1470-2045(25)00018-X. Epub 2025 Apr 9.
5
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
6
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松与硼替佐米、美法仑和泼尼松在不适合移植的新诊断多发性骨髓瘤中的应用：ALCYONE 研究体弱亚组分析。
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):785-798. doi: 10.1016/j.clml.2021.06.005. Epub 2021 Jun 18.
7
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松与新诊断不适合移植的多发性骨髓瘤拉丁美洲的标准治疗的比较：倾向评分匹配分析。
Adv Ther. 2020 Dec;37(12):4996-5009. doi: 10.1007/s12325-020-01521-9. Epub 2020 Oct 16.
8
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
9
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.达雷妥尤单抗与抗肿瘤治疗联合应用对比单纯抗肿瘤治疗用于不适合移植的新诊断成年多发性骨髓瘤患者
Cochrane Database Syst Rev. 2024 May 2;5(5):CD013595. doi: 10.1002/14651858.CD013595.pub2.
10
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.达雷妥尤单抗：在不适合移植的新诊断多发性骨髓瘤联合治疗中的应用评价。
Drugs. 2019 Mar;79(4):447-454. doi: 10.1007/s40265-019-01080-6.

引用本文的文献

1
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.达雷妥尤单抗、硼替佐米、美法仑和泼尼松联合用药与单独使用硼替佐米、美法仑和泼尼松治疗新诊断的不适于移植的多发性骨髓瘤患者的健康相关生活质量：3期OCTANS研究分析
Ann Hematol. 2025 May 23. doi: 10.1007/s00277-025-06303-3.